HT

Healthy Truth Wins Best New Protein Powder Product with Its Organic Cacao Plant-Based Blend

Retrieved on: 
Wednesday, February 8, 2023
USDA, Inulin, HT, Types of chocolate, Digestion, Exercise, Allergy, Dietary supplement

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- HEALTHY TRUTH has been recognized by Retailer News Network for offering the best new product line opportunity in the plant-based protein dietary supplement and snack market. This award-winning company offers its growing customer base a wide variety of USDA-certified organic lactose-free protein powders and nutrition-dense snacks, all of which are ethically sourced, vegan-friendly, and better-tasting (according to many satisfied customers) than those of their competitors -- many of which are larger and better-known brands fighting for an increased revenue share in this very competitive and fast-growing market segment. HEALTHY TRUTH is the superior brand in virtually every important aspect and is on an impressive trajectory. [read complete release]

Key Points: 
  • NEW YORK, Feb. 8, 2023 /PRNewswire/ -- HEALTHY TRUTH has been recognized by Retailer News Network for offering the best new product line opportunity in the plant-based protein dietary supplement and snack market.
  • HEALTHY TRUTH is the superior brand in virtually every important aspect and is on an impressive trajectory.
  • One of HEALTHY TRUTH's most exciting offerings is its Organic Cacao Plant-Based Protein Powder.
  • GO Pro Protein Powder also comes in an unflavored variety, making it perfect to mix in with smoothies, shakes, or favorite recipes.

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

Retrieved on: 
Monday, January 9, 2023
IND, Menopause, Estradiol, Safety, PK, FDA, HT, VMS, Woman, NAMS, Hormone, Investigational New Drug, SAN, Clinical trial, Harvard Medical School, Progesterone, North American Menopause Society, IVR, Birth control, Pharmaceutical industry

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced topline PK results from its Phase 1 / 2 clinical trial of DARE-HRT1 that support the potential of DARE-HRT1 as an effective hormone therapy (HT) based on the levels of hormones released. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a HT regimen. HT is used to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. DARE-HRT1 has the potential to be the first FDA-approved product to offer vaginal delivery of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient monthly format. Daré plans to advance DARE-HRT1 into a single Phase 3 clinical trial to support a new drug application for DARE-HRT1 for the treatment of moderate to severe VMS due to menopause in women with intact uteri.

Key Points: 
  • HT is used to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.
  • DARE-HRT1 has the potential to be the first FDA-approved product to offer vaginal delivery of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient monthly format.
  • The estradiol PK data in that prior DARE-HRT1 Phase 1 study support the potential of DARE-HRT1 as an effective hormone therapy for both VMS and vaginal symptoms associated with menopause.
  • Secondary objectives of the study were to assess the usability, participant tolerability, and preliminary effectiveness of DARE-HRT1 for both the VMS and vaginal symptoms of menopause.

Hersha Hospitality Trust to Report Fourth Quarter 2022 Earnings on February 15, 2023

Retrieved on: 
Thursday, January 5, 2023
Annual report, New York Stock Exchange, Security (finance), NYSE, Webcast, HT, Hersha Hospitality Trust, Hotel

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hersha Hospitality Trust (NYSE: HT) (“Hersha” or the “Company”), owner of luxury and lifestyle hotels in coastal gateway and resort markets, today announced that the Company will release its financial results for the fourth quarter 2022 after the market close on Wednesday, February 15, 2023.

Key Points: 
  • PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hersha Hospitality Trust (NYSE: HT) (“Hersha” or the “Company”), owner of luxury and lifestyle hotels in coastal gateway and resort markets, today announced that the Company will release its financial results for the fourth quarter 2022 after the market close on Wednesday, February 15, 2023.
  • The Company will host a conference call to discuss these results at 9:00 AM Eastern Time on Thursday, February 16, 2023.
  • Hosting the call will be Mr. Neil H. Shah, President and Chief Executive Officer, and Mr. Ashish Parikh, Chief Financial Officer.
  • Hersha Hospitality Trust (HT) is a self-advised real estate investment trust in the hospitality sector, which owns and operates luxury and lifestyle hotels in coastal gateway and resort markets.

Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications

Retrieved on: 
Friday, January 6, 2023
Technology, Biotechnology, Health, Biometrics, Radiology, Pharmaceutical, Oncology, Research, Software, Genetics, Health Technology, Hardware, Science, Clinical Trials, Cancer, Ecosystem, Partnership, Single-cell analysis, Agilent Technologies, Spatial analysis, Organization, Biomarker, Abbeyknockmoy GAA, CLIA, NYSE, Tumor microenvironment, Pathology, Therapy, Value-added reseller, HT, Akoya, Workflow, IHC, Cell, Medical imaging

Agilent and Akoya will partner to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics.

Key Points: 
  • Agilent and Akoya will partner to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics.
  • Under a separate Value-Added Reseller agreement, Akoya Biosciences will distribute and resell Dako Omnis as a part of the end-to-end multiplex solution.
  • “Multiplex tissue analysis has the potential to transform the field of cancer therapeutics and usher in a new era of precision pathology,” said Brian McKelligon, CEO of Akoya Biosciences.
  • “This partnership and the combined strength of both organizations will catalyze the development and deployment of multiplex tissue-based biomarkers for the benefit of our biopharma and CRO partners and, ultimately, patients.“

VETERINARY LEADERS TO SHARE BREAKTHROUGHS ACROSS THE BOARD FOR MORE EFFECTIVE CANCER TREATMENT, NON-INVASIVE DIAGNOSTICS, UNDERSTANDING FELINE PAIN AND SURGERY ON THE SMALLEST PATIENTS

Retrieved on: 
Tuesday, December 20, 2022
Sentinel, Veterinarian, HDI, Textbook, HT, Health, Cat, VMX, COVID-19, Animal, News, Loyal, Epidemiology, Analgesic, Research, Sentinel (comics), Artery, Brain tumor, Patient, Weakness, MRI, Dog, Survival rate, Pandemic, Horse, Subcutaneous tissue, Risk, Bird, Veterinary medicine, Orlando Sentinel, Cancer, Hamster, Skin, Cardiology, Human, Breast cancer, Zoonosis, Family, History, Virus, American Veterinary Medical Association, Brain, Heart, Diagnosis, Life, Multimedia, Rabbit, Ageing, The Marine Mammal Center, Anesthesia, PETS, Degenerative disease, Huber loss, Trauma, Neoplasm, Vein, CT, Seizure, Orange County Convention Center, Sea, Publication, Science, Medical imaging, Dentistry, Pain

ORLANDO, Fla., Dec. 20, 2022 /PRNewswire/ -- From breast cancer surgery on a tiny hedgehog to advanced non-invasive ways to detect cancer, perform heart surgery and measure pain, the veterinary industry continues to provide new, less painful and more successful options to help animals live longer, better quality lives. This comes as good news to pet owners who see and treat their pets as family and increasingly seek the best healthcare possible for them.

Key Points: 
  • Key topics and presenters available for interviews include:
    Note: See the VMX 2023 Full Program for session dates and times.
  • Her session will focus on how the human and veterinary medical communities work together to minimize future outbreaks.
  • The North American Veterinary Community (NAVC) is a nonprofit organization dedicated to supporting and advancing veterinary professionals worldwide.
  • Since 2017, the NAVC has been recognized as one of the Top Workplaces by the Orlando Sentinel.

Hersha Hospitality Trust Announces Special Dividend and Continuation of Quarterly Cash Dividend

Retrieved on: 
Thursday, December 15, 2022
Annual report, NYSE, Security (finance), Hersha Hospitality Trust, Trustee, New York Stock Exchange, HT, Partnership

In addition to this special dividend, the Board also approved a cash dividend of $0.05 per common share and per limited partnership unit for the fourth quarter ending December 31, 2022.

Key Points: 
  • In addition to this special dividend, the Board also approved a cash dividend of $0.05 per common share and per limited partnership unit for the fourth quarter ending December 31, 2022.
  • The proceeds from these sales facilitated a comprehensive refinancing which substantially de-levered our balance sheet and eliminated near-term maturities.
  • The impact of these transformational sales, in conjunction with the cash generation of our portfolio, will lead to $225M in year-end cash holdings.
  • This special dividend, along with the continuation of our common dividend, demonstrates not only the success of our disposition strategy but also our confidence and outlook for our streamlined portfolio.

Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day

Retrieved on: 
Thursday, December 15, 2022
RNA, Immunotherapy, Society, Tumor microenvironment, Health, Software, Akoya, Inflammation, Ecosystem, Pathai, Annual general meeting, Workflow, Society for Immunotherapy of Cancer, HT, Neuroscience, Data analysis, Organization, HIV disease progression rates, SITC, Biomarker, Precision medicine, Automation, Architecture, Biology, Risk management, Microscope, Medical imaging, 3D printing, Panel

MARLBOROUGH, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today highlighted the latest wave of spatial biology innovations, new products, and partnerships that further accelerate and simplify spatial signature discovery and validation, at its second annual Spatial Day event. Company leadership and leading scientists came together to discuss advancements in spatial biology and the progress towards delivering spatial signatures to advance the field of precision medicine.

Key Points: 
  • New products and partnerships further accelerate and simplify identification of actionable spatial signatures, creating unprecedented opportunities to improve patient outcomes
    MARLBOROUGH, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today highlighted the latest wave of spatial biology innovations, new products, and partnerships that further accelerate and simplify spatial signature discovery and validation, at its second annual Spatial Day event.
  • Company leadership and leading scientists came together to discuss advancements in spatial biology and the progress towards delivering spatial signatures to advance the field of precision medicine.
  • At this year’s Spatial Day, the company introduced a suite of ready-to-use PhenoCode™ panels to accelerate the adoption and utilization of the company’s spatial phenotyping solutions for discovery and translational research.
  • As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping.

Platin Audio Showcases New Monaco 5.1.2 at B&H Photo Video SuperStore in New York City

Retrieved on: 
Monday, December 12, 2022
Home Goods, Other Retail, Audio, Video, Consumer Electronics, Technology, Luxury, Mobile, Wireless, Retail, Atmos, HT, WiSA, Dolby Atmos, Bang & Olufsen, Music, Television, Ecosystem, Name, National Wisa Association, Audio, B&H, Harman International, Wireless speaker, Dolby Laboratories, TCL, B&H Photo, Multimedia, Marketing, Senior, CE, Electronics, Sport, Cassette tape, Consumer electronics, LG, Samsung, Platin, Hisense

Platin Audio today announces its newest surround sound system Platin Audio Monaco 5.1.2 is now on display at the B&H Photo Video SuperStore in New York City.

Key Points: 
  • Platin Audio today announces its newest surround sound system Platin Audio Monaco 5.1.2 is now on display at the B&H Photo Video SuperStore in New York City.
  • View the full release here: https://www.businesswire.com/news/home/20221212005257/en/
    Platin Audio Monaco 5.1.2 is now on display at B&H Photo Video SuperStore in New York City.
  • (Graphic: Business Wire)
    To give consumers a first-hand listening experience, Platin Audio is joining the ranks of more than 3,000 technology brands at the B&H Photo Video SuperStore located at 420 9th Ave. in Manhattan, New York.
  • To learn more about Platin Audio and its full suite of products, visit www.platinaudio.us or connect with the brand on Facebook .

WiSA Technologies Launches New App Delivering Powerful and Intuitive Control of WiSA-Enabled TVs, Soundbars, and External Transmitters

Retrieved on: 
Tuesday, December 6, 2022
Teens, Women, Seniors, Men, Mobile, Wireless, Family, IOT (Internet of Things), Consumer, Apps, Applications, Other Entertainment, General Entertainment, TV and Radio, Music, Other Technology, Audio, Video, Software, Electronic Games, Networks, Hardware, Home Goods, Entertainment, Consumer Electronics, Technology, Specialty, Retail, Atmos, Platin, HT, WiSA, Dolby Atmos, Bang & Olufsen, Security (finance), Smartphone, Music, Ecosystem, Name, Google Play, National Wisa Association, Harman International, History of public transport ticketing in New South Wales, OS, Computer Security Act of 1987, CES, Wireless speaker, COVID-19, Vizio, TCL, Multimedia, Growth, CE, IOS, Electronics, Television, Sport, Mobile phone, Online shopping, LG, Samsung, Sony, Hisense

The app is designed to work with any source device that uses WiSA HT, or the new WiSA E embedded software solution, including smart TVs, soundbars, and external transmitters such as the WiSA SoundSend .

Key Points: 
  • The app is designed to work with any source device that uses WiSA HT, or the new WiSA E embedded software solution, including smart TVs, soundbars, and external transmitters such as the WiSA SoundSend .
  • View the full release here: https://www.businesswire.com/news/home/20221206005169/en/
    WiSA Technologies has launched a new app enabling users of WiSA-enabled devices full control of their multichannel audio experience.
  • (Photo: Business Wire)
    As WiSA Technologies launches its new WiSA E technology offerings, it is critical that we provide an app that can be ported to our customers operating systems, said Brett Moyer, CEO of WiSA Technologies.
  • WiSA Technologies, Inc. and the WiSA Technologies, Inc. logo are trademarks of WiSA Technologies, Inc.

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Retrieved on: 
Tuesday, December 13, 2022
HT, Phase II, ImmunoGen, Sirna, Cancer, Radionuclide, Asthma, Antibody, Oligonucleotide, Atopic dermatitis, Endocytosis, Vaccine, Control

NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc. (Nasdaq: IMGN), a leader in developing next generation ADCs. In the joint research effort, Biosion will leverage its proprietary SynTracer® high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs. 

Key Points: 
  • NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc. (Nasdaq: IMGN), a leader in developing next generation ADCs.
  • In the joint research effort, Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs.
  • Biosion is a global, clinical-stage biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases.
  • Biosion and partners have plans to progress additional immune-oncology biologics and antibody drug conjugates into clinical trials for oncology indications over the next year.